brentuximab-vedotin

Overview

Anti-CD30 antibody-drug conjugate (MMAE payload) used in CD30-expressing lymphomas.

Evidence in the corpus

• 12% of 132 nodal PTCL patients in the MSK curative-intent cohort received BV-CH(E)P (brentuximab vedotin plus CHOP/CHOEP) as first-line induction PMID:37078708.
• Heterogeneous inclusion of brentuximab-vedotin across CHOP-based regimens is noted as a limitation for treatment-specific inference of TP53 and CDKN2A prognostic signals PMID:37078708.
• Brentuximab vedotin (BV) uses the same MC-VC-MMAE anti-tubulin ADC warhead platform (MMAE payload, valine-citrulline linker) as the experimental C-MMAE and T-MMAE constructs studied as radiosensitizers; cited as the clinical precedent for ADC-delivered anti-tubulin payloads PMID:27698471.

Resistance mechanisms

• Not reported in corpus.

Cancer types (linked)

• PTCL, ALCL, AITL

Sources

• PMID:37078708
• PMID:27698471

This page was processed by entity-page-writer on 2026-04-15.